Jesse Treu, Ph.D., Board Director
Mr. Treu has been a Partner of Domain since its inception 21 years ago. He has been a director of over 30 early-stage health care companies, 17 of which have so far become successful public companies. Present board memberships include Altea Therapeutics, Aesthetic Sciences, CoLucid, Northstar Neuroscience, Regado Biosciences, SenoRx and Somaxon Pharmaceuticals. Past board memberships include Biosite Diagnostics, Dianon Systems, DNX, GelTex Pharmaceuticals, Inspire Pharmaceuticals, Iomai, Lumisys, NPS Pharmaceuticals, OraPharma, Sepracor, Trimeris and Viagene. He has served as a Founder, President and Chairman of numerous venture stage companies. Prior to the formation of Domain, Mr. Treu had 12 years of experience in the health care industry. Mr. Treu was V.P. of the predecessor organization to The Wilkerson Group, and its venture capital arm, CW Ventures. While at CW Ventures, he served as President and CEO of Microsonics, a pioneer in computer image processing for cardiology. From 1977 through 1982, Mr. Treu led new product development and marketing planning for immunoassay and histopathology products at Technicon Corporation (now Bayer Diagnostics). Mr. Treu began his career with GE in 1973, initially as a research scientist developing thin film optical sensors for immunoassay testing, and subsequently serving on the corporate staff with responsibility for technology assessment and strategic planning.
Education:
B.S. - Rensselaer Polytechnic Institute, 1968
M.A. & Ph.D. - Princeton University, 1971, 1973